The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market ...

Novo Nordisk NVO shares have gained 13.9% in the past month. Several factors related to the company’s pipeline, regulatory ...

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Helge Lund, chair of the Novo Nordisk Board, expressed confidence in the company’s strategy and its ability to execute ...

The company behind the weight loss sensation that transformed bodies and bank accounts across America just showed its own CEO ...

Ozempic maker Novo Nordisk NOVO.B-1.81%decrease ... which has caused a steep stock-price decline and impatience at the nonprofit foundation that controls the company. Lars Fruergaard Jorgensen ...

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

However, investors are advised not to jump to conclusions regarding acquiring/retaining the stock ... to date, Novo Nordisk shares have plunged 23.1% compared with the industry’s decline of ...

The search for a successor is currently underway. The leadership change comes as Novo Nordisk confronts recent market challenges and a decline in its share price since mid-2024. Despite the company’s ...